SCHEMBL505697

SCHEMBL505697

N#CCN1CCN(CC#N)C1c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.44
TP53 P04637 1/20 0.41
MDM2 Q00987 1/20 0.41
POLB P06746 1/20 0.38
GAA P10253 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CHRM2 P08172 3/20 0.36
CHRM4 P08173 3/20 0.36
CHRM5 P08912 3/20 0.36
CHRM1 P11229 3/20 0.36
CHRM3 P20309 3/20 0.36
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
KCNA3 P22001 1/20 0.35
CUL4A Q13619 1/20 0.34
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17679252 0.92 RECQL (0.38) RECQLTP53MDM2POLBGAA
SCHEMBL10153079 0.87 RECQL (0.35) RECQLTP53MDM2POLBCHRM2
SCHEMBL505689 0.85 SIGMAR1 (0.39) RECQLTP53MDM2POLBALDH1A1
SCHEMBL24409946 0.78 ATM (0.35) TP53MDM2ALDH1A1CHRM2CHRM4
SCHEMBL21180934 0.76 CHRM2 (0.36) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL3609864 0.75 CHRNB2 (0.50) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL4619311 0.74 RECQL (0.36) RECQLPOLBGAAALDH1A1CHRM2
SCHEMBL4587533 0.74 KDM4E (0.41) RECQLALDH1A1CHRM2CHRM4CHRM5
SCHEMBL15461422 0.74 PRCP (0.50) RECQLTP53MDM2POLBGAA
SCHEMBL24427032 0.73 P2RX7 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778618-B1 SYNTHESIS OF TRIETHYLENETETRAMINES PHILERA NEW ZEALAND LTD (NZ) 2013-12-25 EP claimed
US-20120029203-A1 Synthesis Of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2012-02-02 US claimed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US claimed
EP-1778618-A4 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORP LTD (NZ) 2008-07-16 EP claimed
EP-1778618-A2 SYNTHESIS OF TRIETHYLENETETRAMINES Protemix Corporation Limited (NZ) 2007-05-02 EP claimed
WO-2006027705-A2 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORPORATION LIMITED (NZ) 2006-03-16 WO claimed
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PHILERA NEW ZEALAND LIMITED (NZ) 2006-02-23 US claimed
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
US-20200148647-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2020-05-14 US disclosed
US-20200148647-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2020-05-14 US disclosed
US-20170226064-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2017-08-10 US disclosed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US disclosed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US disclosed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US disclosed
EP-1778618-A4 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORP LTD (NZ) 2008-07-16 EP disclosed
EP-1778618-A2 SYNTHESIS OF TRIETHYLENETETRAMINES Protemix Corporation Limited (NZ) 2007-05-02 EP disclosed
WO-2006027705-A2 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORPORATION LIMITED (NZ) 2006-03-16 WO disclosed
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PHILERA NEW ZEALAND LIMITED (NZ) 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795150-B2 Synthesis of triethylenetetramines PNMT, TES, TPR RECQL 1538/4885TP53 1755/4885MDM2 920/4885
US-20170226064-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR RECQL 1538/4885TP53 1755/4885MDM2 920/4885
US-20120029203-A1 Synthesis Of Triethylenetetramines PNMT, TES, TPR RECQL 1538/4885TP53 1755/4885MDM2 920/4885
US-20200148647-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR RECQL 1538/4885TP53 1755/4885MDM2 920/4885
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride TET1, TET2, TET3 RECQL 2615/4885TP53 313/4885MDM2 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.